metricas
covid
Buscar en
Archivos de la Sociedad Española de Oftalmología (English Edition)
Toda la web
Inicio Archivos de la Sociedad Española de Oftalmología (English Edition) Spironolactone, a therapeutic alternative in the treatment of diffuse retinal pi...
Journal Information
Vol. 91. Issue 12.
Pages 599-603 (December 2016)
Share
Share
Download PDF
More article options
Visits
108
Vol. 91. Issue 12.
Pages 599-603 (December 2016)
Short communication
Spironolactone, a therapeutic alternative in the treatment of diffuse retinal pigment epitheliopathy
Espironolactona, alternativa terapéutica en el tratamiento de la epiteliopatía difusa crónica
Visits
108
D. Ángel-Pereira
Corresponding author
dangelp300@gmail.com

Corresponding author.
, P. Rocha-Cabrera, L. Cordovés-Dorta, M.J. Losada Castillo, A. Blasco Alberto, J.A. Abreu Reyes
Servicio de Oftalmología, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (4)
Show moreShow less
Abstract
Case report

Two cases are presented of patients with chronic diffuse epitheliopathy (CDE) that showed a favourable response when treated with spironolactone. The first patient had regions of neurosensory detachment (DNS) and the second, multiple DNS, secondary intra-retinal cysts and retinal pigment epithelium detachment.

Discussion

After treatment with spironolactone, both patients showed a visual acuity improvement and structural changes (reduced neurosensory retinal detachment and cystoid degeneration).

Aldosterone receptor agonists (ARA) used for persistent forms of chronic central serous chorioretinopathy show encouraging results and could represent a therapeutic alternative for CDE.

Keywords:
Epitheliopathy
Diffuse
Chronic
Spironolactone
Antagonists
Receptor
Aldosterone
Resumen
Casos clínicos

Se presentan 2 casos clínicos de epiteliopatía difusa crónica (EDC) con respuesta favourable a espironolactona. En el primer paciente se visualizan regiones de desprendimiento neurosensorial (DNS), y en el segundo múltiples DNS, quistes intrarretinianos secundarios y desprendimiento del epitelio pigmentario de la retina.

Discusión

Tras el tratamiento con espironolactona, se observa mejoría de la agudeza visual y de las alteraciones estructurales en ambos pacientes (disminución del DNS y quistes intrarretinianos).

Los fármacos antagonistas de los receptores de aldosterona usados para formas persistentes de coriorretinopatía central serosa (CRCS) tienen resultados alentadores, y podrían ser una alternativa terapéutica en la EDC.

Palabras clave:
Epiteliopatía
Difusa
Crónica
Espironolactona
Antagonistas
Receptores
Aldosterona

Article

These are the options to access the full texts of the publication Archivos de la Sociedad Española de Oftalmología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Archivos de la Sociedad Española de Oftalmología (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.oftale.2020.07.005
No mostrar más